22
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease

      research-article
      a , a , a , b , c , a , b , d ,
      Chemico-Biological Interactions
      Published by Elsevier B.V.
      Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19, Main protease (Mpro), 2-Pyridone, In silico molecular modelling, AutoDock, ACE2, Angiotensin-converting enzyme 2, ADMET, Absorption, distribution, metabolism, excretion, toxicity, clogD, Calculated distribution coefficient, clogP, Calculated partition coefficient, F(20%), Oral bioavailability score to achieve 20% systemic concentration, ΔGcalc, Gibbs free energy, calculated, H-bonds, Hydrogen bonds, HBD, Hydrogen bond donors, IC50, Half maximal inhibitory concentration, Ki, Inhibition constant, LD50, acute oral toxicity median lethal dose, logPapp, Calculated Caco-2 permeability, logS, Calculated aqueous solubility, MPO, Multi-parametric optimization, Mpro, Main protease, PDB, Protein databank, pKa, Acid dissociation constant, PLpro, Papain-like protease, QM, quantum mechanics, R, gas constant, RdRp, RNA-dependent RNA polymerase, RMSD, root mean square deviation, SARS-CoV, Severe acute respiratory syndrome coronavirus, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, T, Absolute temperature, TPSA, Total polar surface area

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The disease, COVID-19, is caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2) for which there is currently no treatment. The SARS-CoV-2 main protease (M pro) is an important enzyme for viral replication. Small molecules that inhibit this protease could lead to an effective COVID-19 treatment. The 2-pyridone scaffold was previously identified as a possible key pharmacophore to inhibit SARS-CoV-2 M pro. A search for natural, antimicrobial products with the 2-pyridone moiety was undertaken herein, and their calculated potency as inhibitors of SARS-CoV-2 M pro was investigated. Thirty-three natural products containing the 2-pyridone scaffold were identified from the literature. An in silico methodology using AutoDock was employed to predict the binding energies and inhibition constants ( K i values) for each 2-pyridone-containing compound with SARS-CoV-2 M pro. This consisted of molecular optimization of the 2-pyridone compound, docking of the compound with a crystal structure of SARS-CoV-2 M pro, and evaluation of the predicted interactions and ligand-enzyme conformations. All compounds investigated bound to the active site of SARS-CoV-2 M pro, close to the catalytic dyad (His-41 and Cys-145). Thirteen molecules had predicted K i values < 1 μM. Glu-166 formed a key hydrogen bond in the majority of the predicted complexes, while Met-165 had some involvement in the complex binding as a close contact to the ligand. Prominent 2-pyridone compounds were further evaluated for their ADMET properties. This work has identified 2-pyridone natural products with calculated potent inhibitory activity against SARS-CoV-2 M pro and with desirable drug-like properties, which may lead to the rapid discovery of a treatment for COVID-19.

          Highlights

          • 2-pyridone-scaffold is an inhibitory pharmacophore for SARS-CoV-2 M pro.

          • Thirty-three natural, antimicrobial products identified with 2-pyridone moiety.

          • All 2-pyridone natural products bind to active site of SARS-CoV-2 M pro in silico.

          • Thirteen molecules found to have potent inhibitory activity against SARS-CoV-2 M pro.

          • Inhibition of SARS-CoV-2 by natural 2-pyridones may lead to treatment of COVID-19.

          Related collections

          Most cited references75

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          A pneumonia outbreak associated with a new coronavirus of probable bat origin

          Since the outbreak of severe acute respiratory syndrome (SARS) 18 years ago, a large number of SARS-related coronaviruses (SARSr-CoVs) have been discovered in their natural reservoir host, bats 1–4 . Previous studies have shown that some bat SARSr-CoVs have the potential to infect humans 5–7 . Here we report the identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China. The epidemic, which started on 12 December 2019, had caused 2,794 laboratory-confirmed infections including 80 deaths by 26 January 2020. Full-length genome sequences were obtained from five patients at an early stage of the outbreak. The sequences are almost identical and share 79.6% sequence identity to SARS-CoV. Furthermore, we show that 2019-nCoV is 96% identical at the whole-genome level to a bat coronavirus. Pairwise protein sequence analysis of seven conserved non-structural proteins domains show that this virus belongs to the species of SARSr-CoV. In addition, 2019-nCoV virus isolated from the bronchoalveolar lavage fluid of a critically ill patient could be neutralized by sera from several patients. Notably, we confirmed that 2019-nCoV uses the same cell entry receptor—angiotensin converting enzyme II (ACE2)—as SARS-CoV.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            A new coronavirus associated with human respiratory disease in China

            Emerging infectious diseases, such as severe acute respiratory syndrome (SARS) and Zika virus disease, present a major threat to public health 1–3 . Despite intense research efforts, how, when and where new diseases appear are still a source of considerable uncertainty. A severe respiratory disease was recently reported in Wuhan, Hubei province, China. As of 25 January 2020, at least 1,975 cases had been reported since the first patient was hospitalized on 12 December 2019. Epidemiological investigations have suggested that the outbreak was associated with a seafood market in Wuhan. Here we study a single patient who was a worker at the market and who was admitted to the Central Hospital of Wuhan on 26 December 2019 while experiencing a severe respiratory syndrome that included fever, dizziness and a cough. Metagenomic RNA sequencing 4 of a sample of bronchoalveolar lavage fluid from the patient identified a new RNA virus strain from the family Coronaviridae, which is designated here ‘WH-Human 1’ coronavirus (and has also been referred to as ‘2019-nCoV’). Phylogenetic analysis of the complete viral genome (29,903 nucleotides) revealed that the virus was most closely related (89.1% nucleotide similarity) to a group of SARS-like coronaviruses (genus Betacoronavirus, subgenus Sarbecovirus) that had previously been found in bats in China 5 . This outbreak highlights the ongoing ability of viral spill-over from animals to cause severe disease in humans.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

              Structure of the nCoV trimeric spike The World Health Organization has declared the outbreak of a novel coronavirus (2019-nCoV) to be a public health emergency of international concern. The virus binds to host cells through its trimeric spike glycoprotein, making this protein a key target for potential therapies and diagnostics. Wrapp et al. determined a 3.5-angstrom-resolution structure of the 2019-nCoV trimeric spike protein by cryo–electron microscopy. Using biophysical assays, the authors show that this protein binds at least 10 times more tightly than the corresponding spike protein of severe acute respiratory syndrome (SARS)–CoV to their common host cell receptor. They also tested three antibodies known to bind to the SARS-CoV spike protein but did not detect binding to the 2019-nCoV spike protein. These studies provide valuable information to guide the development of medical counter-measures for 2019-nCoV. Science, this issue p. 1260
                Bookmark

                Author and article information

                Journal
                Chem Biol Interact
                Chem Biol Interact
                Chemico-Biological Interactions
                Published by Elsevier B.V.
                0009-2797
                1872-7786
                2 December 2020
                2 December 2020
                : 109348
                Affiliations
                [a ]Department of Medical Neuroscience, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, B3H 4R2, Canada
                [b ]Department of Chemistry and Physics, Faculty of Arts and Science, Mount Saint Vincent University, Halifax, Nova Scotia, B3M 2J6, Canada
                [c ]Department of Chemistry, Faculty of Science, Saint Mary's University, Halifax, Nova Scotia, B3H 3C3, Canada
                [d ]Department of Medicine (Neurology), Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, B3H 4R2, Canada
                Author notes
                []Corresponding author. Room 1308, Camp Hill Veterans' Memorial, 5955 Veterans' Memorial Lane, Halifax, Nova Scotia, B3H 2E1, Canada.
                Article
                S0009-2797(20)31291-6 109348
                10.1016/j.cbi.2020.109348
                7710351
                33278462
                20662bf2-ea51-47fe-9f94-c381c9c1f732
                © 2020 Published by Elsevier B.V.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 1 August 2020
                : 5 October 2020
                : 26 November 2020
                Categories
                Article

                severe acute respiratory syndrome coronavirus 2 (sars-cov-2),covid-19,main protease (mpro),2-pyridone,in silico molecular modelling,autodock,ace2, angiotensin-converting enzyme 2,admet, absorption, distribution, metabolism, excretion, toxicity,clogd, calculated distribution coefficient,clogp, calculated partition coefficient,f(20%), oral bioavailability score to achieve 20% systemic concentration,δgcalc, gibbs free energy, calculated,h-bonds, hydrogen bonds,hbd, hydrogen bond donors,ic50, half maximal inhibitory concentration,ki, inhibition constant,ld50, acute oral toxicity median lethal dose,logpapp, calculated caco-2 permeability,logs, calculated aqueous solubility,mpo, multi-parametric optimization,mpro, main protease,pdb, protein databank,pka, acid dissociation constant,plpro, papain-like protease,qm, quantum mechanics,r, gas constant,rdrp, rna-dependent rna polymerase,rmsd, root mean square deviation,sars-cov, severe acute respiratory syndrome coronavirus,sars-cov-2, severe acute respiratory syndrome coronavirus 2,t, absolute temperature,tpsa, total polar surface area

                Comments

                Comment on this article

                scite_

                Similar content509

                Cited by11

                Most referenced authors3,090